Leerink Partnrs Has Bullish Forecast for NBIX Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 EPS forecast for Neurocrine Biosciences to $1.71, up from a previous estimate of $1.58, indicating bullish sentiment.
• Neurocrine Biosciences reported an EPS of $1.06, exceeding analysts' expectations of $0.98, with revenues of $687.5 million for the quarter.
• There is significant institutional interest in the company, with 92.59% of its stock owned by hedge funds and other institutional investors, highlighting strong market confidence.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for Neurocrine Biosciences in a research note issued to investors on Wednesday, July 30th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $1.71 per share for the quarter, up from their prior estimate of $1.58. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' FY2025 earnings at $4.60 EPS and FY2028 earnings at $11.55 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.08. The business had revenue of $687.50 million for the quarter, compared to analysts' expectations of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The business's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.63 EPS.

Other analysts also recently issued reports about the company. Wall Street Zen raised Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Saturday. Royal Bank Of Canada dropped their price objective on shares of Neurocrine Biosciences from $146.00 to $144.00 and set an "outperform" rating for the company in a report on Thursday. Wedbush raised their price objective on shares of Neurocrine Biosciences from $137.00 to $141.00 and gave the stock an "outperform" rating in a research report on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the company a "neutral" rating in a report on Thursday. Finally, Morgan Stanley increased their price target on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company an "overweight" rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $160.90.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $128.91 on Monday. The business's 50 day moving average price is $128.26 and its 200 day moving average price is $120.74. The company has a market cap of $12.79 billion, a price-to-earnings ratio of 38.14, a PEG ratio of 1.11 and a beta of 0.25. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $157.40.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after buying an additional 135 shares during the period. Huntington National Bank raised its stake in shares of Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after acquiring an additional 97 shares in the last quarter. WPG Advisers LLC purchased a new position in Neurocrine Biosciences in the first quarter valued at $32,000. Smallwood Wealth Investment Management LLC acquired a new position in Neurocrine Biosciences during the 1st quarter worth $34,000. Finally, GeoWealth Management LLC increased its holdings in Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after purchasing an additional 102 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of the business's stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $135.00, for a total transaction of $61,695.00. Following the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jude Onyia sold 59,819 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the transaction, the insider directly owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,251 shares of company stock worth $11,672,602. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.